CGM

Investment Agreement with CVC & voluntary public tender offer Investor & Analyst Call

Daniela Hommel, CFO December 9, 2024

Disclaimer

The information provided in this presentation pertaining to CompuGroup Medical SE & Co. KGaA (the "Company"), comprise the written materials/slides for presentations or discussions on the occasion of an investor conference, meeting or conference call ("Meeting"). Whilst all reasonable care has been taken to ensure that the information and facts stated herein as well as oral statements made in the Meeting are accurate and that the opinions and expectations contained herein and orally received during the Meeting are fair and reasonable, no representation or warranty, express or implied, is given by or on behalf of the Company, any of its board members, or any other person as to the accuracy or completeness of the information and/or opinions and no liability as to the accuracy of such information and/or opinions is accepted. The information provided in this presentation as well as during the Meeting contain forward looking statements which involve risks and uncertainties. These forward-looking statements speak only as of the date of the documents and are based on numerous assumptions which may or may not prove to be correct. The actual performance and results of the business of the Company could differ materially from the performance and results discussed in this document or in any other information received during the Meeting. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements or other information contained herein or received during the Meeting whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on forward-looking statements or financial projections. The information contained in this presentation and/or received during the Meeting does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto.



Transaction highlights



CGM enters into investment agreement with CVC to support innovation & growth



Managing Directors, Administrative & Supervisory Board welcome partnership ¹⁾



Founding family Gotthardt & Dr. Koop will retain majority stake of 50.1%



Customers to benefit from partnership driving quality, innovation & growth



CVC to launch voluntary tender offer for €22.00 at a premium of 51.1% ²⁾




Offer subject to minimum acceptance threshold of 17% and regulatory clearance

CompuGroup

¹⁾ subject to their review of the Offer Document to be published by CVC
²⁾ 51.1% versus 3-months VWAP (€14.56) as of December 6, 2024

With our unique customer base in healthcare ...



CVC to fully support our strategic key priorities



Improve organization & core processes

Synchronizing our great products




Enhance patient journey by connected products Innovative digital co-pilot functions



Provide value adding modules for customers



CVC aims to become long-term oriented anchor shareholder via public tender offer



Strategic partnership with CVC

- Gotthardt family and Dr Koop to remain majority shareholders with 50.1% stake – CGM stays a family-owned business
- Frank Gotthardt to remain Chairman of Administrative Board. Prof. Dr. med. Daniel Gotthardt to remain CEO & Admin Board member
- CVC has extensive experience in long-term partnerships with familyowned businesses and within software & healthcare industries
- CVC to fully support CGM's strategy, no change in headquarters or locations planned
- Parties agree not to enter into a domination and/or profit and loss • **agreement** for a period of at least two years after closing of the offer

Voluntary public tender offer

- Tender offer to all free float shareholders at a price of €22.00 per share, a premium³⁾ of 51.1% vs. 3M VWAP and of 33.5% vs. Dec 6, 2024
- Minimum acceptance threshold of 17% and customary closing • conditions (e.g., antitrust)

Joint goal to reliably empower medical professionals with next generation products and strong customer support

Investor & Analyst Call Dec 9, 2024 6

¹⁾ GT 1 Vermögensverwaltung GmbH. largest single shareholder in CGM, controlled by Frank Gotthardt ²⁾ via SCUR-Alpha 269 GmbH, controlled by CVC Capital Partners plc. ³⁾ 51.1% versus 3-months VWAP (€14.56) and 33.5% as of closing price on December 6, 2024 (€16.48) ⁴⁾ Total number of shares also includes 3.7% in treasury shareholdings



Offer gives CGM shareholders the option to realize value in immediately at significant premium to current trading

Significant premium for non-control transaction

- **51.1% premium** to **3M VWAP of €14.56** as of December 6, 2024
- 33.5% premium to closing share price of €16.48 on December 6, 2024
- Offer price of €22.00 exceeds the average analyst target price of ~€20

Continued investment path under private ownership

- Subsequent delisting from the stock exchange envisaged
- No upside from integration measures or synergies
- Alignment with CVC on continued high investments into innovation and growth

CompuGroup

Transaction timeline – Next steps

This week

- Announcement of investment agreement & voluntary public tender offer
- Filing of public tender offer document with BaFin

December 2024

- Publication of tender offer document
- Reasoned statement by CGM management and Supervisory Board
- Expected beginning of initial acceptance offer period



H1 2025

- Initial acceptance offer period planned to expire in January
- Closing subject to customary closing conditions (e.g., antitrust) expected within H1 2025



Investor Relations contact

For further information please contact

Claudia Thomé

Senior Vice President Investor Relations T: +49 (0) 160 3630362 claudia.thome@cgm.com

Frederic Freichel

Senior Manager Investor Relations T: +49 (0) 170 3759834 frederic.freichel@cgm.com

CompuGroup Medical SE & Co. KGaA

Maria Trost 21 56070 Koblenz Germany E-Mail: <u>investor@cgm.com</u> ISIN DE000A288904 WKN A28890 Frankfurt Stock Exchange SDAX / TecDAX

CompuGroup